0 Comments
0 Shares
881 Views
0 Reviews
Search
Discover new people, create new connections and make new friends
- Please log in to like, share and comment!
- Mammography Is Expected To Witness High Growth Owing To Increasing Breast Cancer CasesMarket Dynamics: One of the major drivers for the growth of the mammography market is the increasing incidence of breast cancer cases across the globe. As per the World Health Organisation (WHO), breast cancer is the most common cancer in women worldwide. In 2020, there were an estimated 2.3 million women diagnosed with breast cancer globally. Early detection of breast cancer through regular...0 Comments 0 Shares 601 Views 0 Reviews
- Medical Device Connectivity is driven by rising adoption of connected healthcare devicesMarket OverviewMedical device connectivity enables the secure transmission of medical device data to clinical or home health care providers. It plays a critical role in remote patient monitoring and more efficient utilization of healthcare resources. Increasing adoption of IoT based medical devices and growing deployment of online patient portals is accelerating the demand for seamless exchange...0 Comments 0 Shares 684 Views 0 Reviews
- PARP Inhibitors: A Revolutionary Cancer Treatment OptionCancer treatments have advanced significantly in recent decades, but the search continues for therapies that are more effective and less toxic for patients. A class of drugs called PARP inhibitors has emerged as a promising new option, particularly for certain types of breast, ovarian, and other cancers. These inhibitors target DNA repair pathways in cancer cells, helping chemotherapy and...0 Comments 0 Shares 744 Views 0 Reviews
- Rising Incidences of Cancer of PARP Inhibitor MarketThe global PARP Inhibitor Market is estimated to be valued at US$ 6.13 Bn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. SWOT Analysis Strength: Parp inhibitor drugs have shown promising results in clinical trials for breast cancer and ovarian cancer...0 Comments 0 Shares 1441 Views 0 Reviews